Quentin Hill: UK Will Have Access to Generic Eltrombopag
Quentin Hill, Honorary Clinical Associate Professor at University of Leeds, shared a post on LinkedIn:
“From October 2025, the UK will have access to generic eltrombopag. Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licenced treatments for immune thrombocytopenia (ITP).
While these treatments are not identical, their effectiveness is broadly similar and greater use of generic eltrombopag will result in a substantial, multi-million-pound, cost saving to the NHS.
In a joint position statement, the UK ITP Forum and UK ITP Support Association have recommended generic eltrombopag as the preferred initial TPO RA for use second line in ITP. However patients currently stabilised/established on a different TPO RA should continue with their treatment, and access to alternative NICE approved TPO RA (romiplostim, avatrombopag) should continue.”
The full published position statement can be found here.
Stay updated with Hemostasis Today.
-
Nov 10, 2025, 10:16Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
-
Nov 10, 2025, 10:15Laurent Bertoletti Invites You to the Joint INNOVTE and GITA Meeting on Hormones and Thrombosis
-
Nov 10, 2025, 10:15Christopher Cannon: DOAC Monotherapy Wins Again
-
Nov 10, 2025, 10:14Marieke Kruip on Sex differences in Outcomes of VKA Treatment in Patients with Mechanical Heart Valve
-
Nov 10, 2025, 10:14Ana Paula Lacombe: From Research to Bedside, Innovation in Stroke Care is Moving Fast!
-
Nov 10, 2025, 10:13Jan Sloves: Understanding Iliofemoral DVT – What You Can’t Afford to Miss
-
Nov 10, 2025, 10:12Mohamed Rawy Shares a Comprehensive Guide For Anticoagulation
-
Nov 10, 2025, 10:10Marc Carrier: Proud to Share the Results of the WAVe Study
-
Nov 10, 2025, 10:07Frederik Denorme – The New PI at the Laboratory of Cell Biology and Histology at University of Antwerp